Current Report Filing (8-k)
May 13 2022 - 04:40PM
Edgar (US Regulatory)
NASDAQ false 0001205922 0001205922
2022-05-12 2022-05-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 12, 2022
Vaccinex, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
Delaware |
|
001-38624 |
|
16-1603202 |
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
1895 Mount Hope Avenue, Rochester,
New York |
|
14620 |
|
(Address of principal executive
offices) |
|
(Zip Code) |
(585) 271-2700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, par value $0.0001 per
share |
|
VCNX |
|
Nasdaq Capital
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
| Item 5.07 |
Submission of Matters to a Vote of Security Holders.
|
At the annual meeting of stockholders of the Company held on
May 12, 2022, the Company’s stockholders voted on the matters
described below.
| |
Proposal 1. |
The Company’s stockholders elected the following nominees as
directors, each to serve for a three-year term expiring in
2025.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Director Nominee
|
|
Votes For |
|
|
Authority Withheld |
|
|
Broker Non-Votes |
|
|
Chrystyna Bedrij Stecyk
|
|
|
20,338,061 |
|
|
|
527,786 |
|
|
|
5,819,555 |
|
|
Bala S. Manian
|
|
|
20,286,510 |
|
|
|
579,337 |
|
|
|
5,819,555 |
|
| |
Proposal 2. |
The Company’s stockholders ratified the appointment of
Deloitte & Touche LLP as the Company’s independent
registered public accounting firm for the fiscal year ending
December 31, 2022.
|
|
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
| 26,332,224 |
|
185,405 |
|
167,773 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
VACCINEX, INC. |
| Date: May 13,
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Scott E. Royer
|
|
|
|
|
|
|
Scott E. Royer |
|
|
|
|
|
|
Chief Financial Officer |
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Apr 2023 to May 2023
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From May 2022 to May 2023
